Drug Trial Radar · NCT03984591
A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure
Last checked: Nov 20, 2026Latest source record: Feb 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
7,200
Planned (sponsor's estimate)
Start
Nov 1, 2020
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Bispebjerg HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Copenhagen University Hospital, Rigshospitalet
- First posted
- Jun 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objective The objective is to compare the efficacy of spironolactone and eplerenone on clinical outcome in patients with heart failure and a reduced ejection fraction. Method The study is a crossover cluster randomized trial. Each heart failure clinic in Denmark will be allocated to four periods (clusters): two periods with spironolactone and two periods with eplerenone as first drug. The planned total participation time for each department is 4 years and we estimate that data from 7200 patients will be accrued in this period. Endpoints will be assessed through Danish National Registries.
Conditions
- Systolic Heart Failure
Interventions
EplerenoneDrug
Eplerenone according to guidelines
SpironolactoneDrug
Spironolactone according to guidelines
Primary outcomes
What the sponsor says the trial is designed to measure.
- MortalityTime frame: 5 years
- Mortality or hospitalization for heart failureTime frame: 6 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bispebjerg Hospital
Copenhagen, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.